https://www.pharmaradar360.com/article/evonik-sells-hanau-pharmaceutical-ingredients-production-assets-to-prochem-6209a971c5dc25cbPharma Surgeen2026-06-23T03:12:22.000ZEvonik Sells Hanau Pharmaceutical Ingredients Production Assets To ProChemhttps://www.pharmaradar360.com/article/biotech-chief-says-industry-in-better-place-after-fda-changes-bea29e624d847877Pharma Surgeen2026-06-23T02:14:00.000ZBiotech Chief Says Industry in ‘Better Place’ After FDA Changeshttps://www.pharmaradar360.com/article/innovent-pfizer-deal-makes-joint-development-commercialization-pillar-in-biotech-ddb634b0622e63edPharma Surgeen2026-06-23T01:22:00.000ZInnovent-Pfizer deal makes joint development, commercialization pillar in biotech global pushhttps://www.pharmaradar360.com/article/why-this-mid-cap-biotech-could-be-the-dark-horse-threat-to-eli-lilly-and-novo-no-66bc714f3c69417cPharma Surgeen2026-06-23T01:11:55.000ZWhy This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordiskhttps://www.pharmaradar360.com/article/why-this-mid-cap-biotech-could-be-the-dark-horse-threat-to-eli-lilly-and-novo-no-78d5a8bfa98274adPharma Surgeen2026-06-23T00:35:00.000ZWhy This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordiskhttps://www.pharmaradar360.com/article/bio-usa-2026-china-s-biotech-rise-puts-korea-on-notice-koreabio-vp-0e4b14abe840ac58Pharma Surgeen2026-06-23T00:26:47.000Z[BIO USA 2026] China’s biotech rise puts Korea on notice: KoreaBIO VPhttps://www.pharmaradar360.com/article/ah-008-achieves-dual-regulatory-milestones-with-u-s-fda-ind-clearance-and-taiwan-bc85d2c9a1e61e7fPharma Surgeen2026-06-23T00:01:48.000ZAH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designationhttps://www.pharmaradar360.com/article/drug-label-update-unspecified-product-8fa44caec5530ce6Pharma Surgeen2026-06-23T00:00:00.000ZDrug label update: unspecified producthttps://www.pharmaradar360.com/article/clinical-and-histopathological-profile-of-breast-cancer-based-on-her2-stratifica-3865eb61b3cd6f94Pharma Surgeen2026-06-23T00:00:00.000ZClinical and Histopathological Profile of Breast Cancer Based on HER2 Stratification ASCO/CAP 2018: Analysis of HER2-Positive, Negative, Low, and Ultralowhttps://www.pharmaradar360.com/article/garengeot-hernia-preperitoneal-approach-in-the-context-of-strangulation-case-rep-23e74bd2a9a1ad57Pharma Surgeen2026-06-23T00:00:00.000ZGarengeot hernia: preperitoneal approach in the context of strangulation, case reporthttps://www.pharmaradar360.com/article/does-the-use-of-liposomal-bupivacaine-in-hip-fracture-surgery-have-any-advantage-f6982e4c584955f5Pharma Surgeen2026-06-23T00:00:00.000ZDoes the Use of Liposomal Bupivacaine in Hip Fracture Surgery Have Any Advantage Over Conventional Analgesia for Postoperative Pain Control?https://www.pharmaradar360.com/article/early-procalcitonin-kinetics-and-28-day-mortality-in-critical-illness-a-pragmati-02c9af63363a52b3Pharma Surgeen2026-06-23T00:00:00.000ZEarly procalcitonin kinetics and 28-day mortality in critical illness: a pragmatic Bayesian modelling approachhttps://www.pharmaradar360.com/article/national-comparability-and-inter-laboratory-performance-of-cortisol-immunoassays-737d636594b4166aPharma Surgeen2026-06-23T00:00:00.000ZNational comparability and inter-laboratory performance of cortisol immunoassays and LC-MS/MS methodshttps://www.pharmaradar360.com/article/enhancing-the-norepinephrine-transporter-expression-and-lt-sup-gt-211-lt-sup-gt-b4be4d97fb686b5cPharma Surgeen2026-06-23T00:00:00.000ZEnhancing the Norepinephrine Transporter Expression and [<sup>211</sup>At]MABG Uptake with Vorinostat Preloading in the Pheochromocytoma Modelhttps://www.pharmaradar360.com/article/lipopolysaccharide-induced-changes-in-facial-expression-and-orofacial-movement-i-26681344f2d0a333Pharma Surgeen2026-06-23T00:00:00.000ZLipopolysaccharide-Induced Changes in Facial Expression and Orofacial Movement in Micehttps://www.pharmaradar360.com/article/clinical-electrophysiological-and-neuropathological-features-of-peripheral-neuro-a5078c8d6d410f32Pharma Surgeen2026-06-23T00:00:00.000ZClinical, Electrophysiological, and Neuropathological Features of Peripheral Neuropathies in People With T-Cell Lymphoproliferative Disorderhttps://www.pharmaradar360.com/article/clinical-reasoning-a-32-year-old-woman-with-progressive-vision-loss-and-confusio-191667e5dc6f22e5Pharma Surgeen2026-06-23T00:00:00.000ZClinical Reasoning: A 32-Year-Old Woman With Progressive Vision Loss and Confusionhttps://www.pharmaradar360.com/article/clinical-outcomes-and-parental-of-two-stainless-steel-crown-systems-in-pediatric-e4dc2189d250e2d7Pharma Surgeen2026-06-23T00:00:00.000ZClinical outcomes and parental of two stainless steel crown systems in pediatric patients: a retrospective observational cohort studyhttps://www.pharmaradar360.com/article/low-dose-intrathecal-morphine-versus-intrathecal-fentanyl-for-post-caesarean-ana-8257ba3ef8bb526fPharma Surgeen2026-06-23T00:00:00.000ZLow-dose intrathecal morphine versus intrathecal fentanyl for post-caesarean analgesia in a resource-constrained setting: a pragmatic randomised trialhttps://www.pharmaradar360.com/article/a-slow-regular-rhythm-after-tavr-a-clinical-reasoning-exercise-5b37a5ccbaab2da6Pharma Surgeen2026-06-23T00:00:00.000ZA Slow Regular Rhythm After TAVR: A Clinical Reasoning Exercisehttps://www.pharmaradar360.com/article/angiotensin-receptor-neprilysin-inhibitor-in-heart-failure-with-preserved-ejecti-eba015785baed931Pharma Surgeen2026-06-23T00:00:00.000ZAngiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trialhttps://www.pharmaradar360.com/article/laroprovstat-the-first-oral-small-molecule-pcsk9-inhibitor-for-the-treatment-of-5ab6a734084092d7Pharma Surgeen2026-06-23T00:00:00.000ZLaroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patientshttps://www.pharmaradar360.com/article/active-and-passive-knitting-rhythm-on-eeg-909cd8ff72f7e7bePharma Surgeen2026-06-23T00:00:00.000ZActive and Passive Knitting Rhythm on EEGhttps://www.pharmaradar360.com/article/anatomy-and-structural-connectivity-of-the-opercula-43c308627870f779Pharma Surgeen2026-06-23T00:00:00.000ZAnatomy and Structural Connectivity of the Operculahttps://www.pharmaradar360.com/article/navigating-hantavirus-risk-in-transplantation-implications-for-clinical-practice-9678c597609254d1Pharma Surgeen2026-06-23T00:00:00.000ZNavigating Hantavirus Risk in Transplantation: Implications for Clinical Practicehttps://www.pharmaradar360.com/article/effect-of-a-liquid-crystal-vein-locator-on-intravenous-catheterization-in-young-43e4ca188cb0700dPharma Surgeen2026-06-23T00:00:00.000ZEffect of a liquid crystal vein locator on intravenous catheterization in young children: a randomized trialhttps://www.pharmaradar360.com/article/auditory-involvement-in-inflammatory-bowel-disease-clinical-predictors-and-progn-7d25a828ef951125Pharma Surgeen2026-06-23T00:00:00.000ZAuditory Involvement in Inflammatory Bowel Disease: Clinical Predictors and Prognostic Implicationshttps://www.pharmaradar360.com/article/home-based-trimodal-prehabilitation-before-lung-resection-a-single-center-random-20766de38d39e2eePharma Surgeen2026-06-23T00:00:00.000ZHome-based trimodal prehabilitation before lung resection: a single-center randomized controlled trialhttps://www.pharmaradar360.com/article/a-commentary-on-clinical-outcomes-of-norepinephrine-phenylephrine-vs-norepinephr-c82a0742df1a61f7Pharma Surgeen2026-06-23T00:00:00.000ZA commentary on “Clinical outcomes of norepinephrine-phenylephrine vs. norepinephrine-vasopressin in septic shock: a retrospective cohort study”https://www.pharmaradar360.com/article/excerpts-from-march-april-2025-issue-of-acce-news-0e93327c8e86f993Pharma Surgeen2026-06-23T00:00:00.000ZExcerpts from March-April 2025 Issue of ACCE Newshttps://www.pharmaradar360.com/article/risk-management-7-safety-service-contract-management-ad357e6c88415d57Pharma Surgeen2026-06-23T00:00:00.000ZRisk Management 7 Safety Service Contract Managementhttps://www.pharmaradar360.com/article/doctronic-raises-40-billion-in-series-b-funding-4553886b441da389Pharma Surgeen2026-06-23T00:00:00.000ZDoctronic Raises $40 Billion in Series B Fundinghttps://www.pharmaradar360.com/article/osu-chs-tops-us-news-rankings-in-serving-health-care-shortage-areas-3d2a35bfa6f51abcPharma Surgeen2026-06-23T00:00:00.000ZOSU-CHS Tops US News Rankings in Serving Health Care Shortage Areashttps://www.pharmaradar360.com/article/circa-scientific-inc-appoints-medtech-executive-vafa-jamali-to-board-of-director-781a2e622a0e39caPharma Surgeen2026-06-23T00:00:00.000ZCIRCA Scientific, Inc. Appoints MedTech Executive Vafa Jamali to Board of Directorshttps://www.pharmaradar360.com/article/the-qsmr-shift-why-htm-is-the-new-frontline-of-hospital-risk-bef3bc8bb3c850aePharma Surgeen2026-06-23T00:00:00.000ZThe QSMR Shift: Why HTM Is the New Frontline of Hospital Riskhttps://www.pharmaradar360.com/article/reasons-for-different-laboratory-results-in-northern-sudan-case-study-in-merowe-3e9a6fa60b9006abPharma Surgeen2026-06-23T00:00:00.000ZReasons for Different Laboratory Results in Northern Sudan (Case Study in Merowe)https://www.pharmaradar360.com/article/transfer-learning-for-low-resource-genomic-mutation-detection-84b7c8196cb3e15bPharma Surgeen2026-06-23T00:00:00.000ZTransfer Learning for Low-resource Genomic Mutation Detectionhttps://www.pharmaradar360.com/article/response-to-panteghini-about-analytical-performance-specifications-for-immunosup-4e8f23e0fdb2702cPharma Surgeen2026-06-23T00:00:00.000ZResponse to Panteghini “About Analytical Performance Specifications for Immunosuppressive Drug Measurements”https://www.pharmaradar360.com/article/postsurgical-care-in-nail-surgery-recommendations-based-on-evidence-and-clinical-182f28ccfe2ce5f6Pharma Surgeen2026-06-23T00:00:00.000ZPostsurgical Care in Nail Surgery: Recommendations Based on Evidence and Clinical Experiencehttps://www.pharmaradar360.com/article/are-age-based-cutoffs-for-tha-logically-consistent-881f6dfe5985adb0Pharma Surgeen2026-06-23T00:00:00.000ZAre Age-based Cutoffs for THA Logically Consistent?https://www.pharmaradar360.com/article/corr-insights-are-lgbtq-allyship-symbols-associated-with-patient-trust-in-the-or-13e925a5551b5e3aPharma Surgeen2026-06-23T00:00:00.000ZCORR Insights®: Are LGBTQ+ Allyship Symbols Associated With Patient Trust in the Orthopaedic Surgeon? A Dual Cohort Surveyhttps://www.pharmaradar360.com/article/preoperative-distal-motor-latency-testing-and-long-term-outcomes-in-combined-lum-0bdb8751df8f878cPharma Surgeen2026-06-23T00:00:00.000ZPreoperative Distal Motor Latency Testing and Long-Term Outcomes in Combined Lumbar Spinal Stenosishttps://www.pharmaradar360.com/article/clinical-accuracy-and-applications-of-large-language-models-in-pediatric-orthope-64467496eb7263b3Pharma Surgeen2026-06-23T00:00:00.000ZClinical accuracy and applications of large language models in pediatric orthopedics: a systematic reviewhttps://www.pharmaradar360.com/article/comparative-10-year-performance-of-mammography-artificial-intelligence-polygenic-d1287b6b520cdd2cPharma Surgeen2026-06-23T00:00:00.000ZComparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research Bankhttps://www.pharmaradar360.com/article/heart-failure-inequality-and-the-decades-before-admission-2f3e36c67478b065Pharma Surgeen2026-06-23T00:00:00.000ZHeart failure, inequality, and the decades before admissionhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-infigratinib-in-patients-with-refractory-advanced-gastric-33d7f14c42dc93a7Pharma Surgeen2026-06-23T00:00:00.000ZEfficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trialhttps://www.pharmaradar360.com/article/from-relapse-to-survival-real-world-clinical-impact-of-a-multimodal-approach-in-959cfed93bd0cc14Pharma Surgeen2026-06-23T00:00:00.000ZFrom relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastomahttps://www.pharmaradar360.com/article/how-teva-s-ecopipam-tourette-nda-and-austedo-data-will-impact-teva-pharmaceutica-7ef5373b8c703795Pharma Surgeen2026-06-22T23:41:56.000ZHow Teva’s Ecopipam Tourette NDA and AUSTEDO Data Will Impact Teva Pharmaceutical Industries (TEVA) Investorshttps://www.pharmaradar360.com/article/did-new-voxzogo-and-bmn-333-data-just-shift-biomarin-pharmaceutical-s-bmrn-inves-c70a1d02c6358ffaPharma Surgeen2026-06-22T23:41:56.000ZDid New VOXZOGO and BMN 333 Data Just Shift BioMarin Pharmaceutical's (BMRN) Investment Narrative?https://www.pharmaradar360.com/article/majority-of-americans-value-women-s-safety-over-ease-of-abortion-drug-access-5ae088def45bbd22Pharma Surgeen2026-06-22T23:17:02.000ZMajority of Americans Value Women’s Safety over Ease of Abortion Drug Accesshttps://www.pharmaradar360.com/article/health-brief-fda-signals-reset-in-drug-reviews-03da7d5f869b1c43Pharma Surgeen2026-06-22T23:07:33.000ZHealth Brief: FDA signals reset in drug reviewshttps://www.pharmaradar360.com/article/nuvectis-announces-strategic-portfolio-expansion-via-license-agreement-for-ex-ch-9b9cb853baff095cPharma Surgeen2026-06-22T22:18:52.000ZNuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compoundshttps://www.pharmaradar360.com/article/fda-launches-pilot-to-speed-drug-testing-as-china-surges-in-biotech-race-636d335d2f832c3bPharma Surgeen2026-06-22T21:54:08.000ZFDA launches pilot to speed drug testing as China surges in biotech racehttps://www.pharmaradar360.com/article/ups-adds-27-cold-transfer-facilities-for-pharmaceutical-shipping-75cdcad87c620595Pharma Surgeen2026-06-22T21:53:36.000ZUPS adds 27 cold transfer facilities for pharmaceutical shippinghttps://www.pharmaradar360.com/article/chart-master-is-it-time-to-buy-biotech-3a4b344cd466e810Pharma Surgeen2026-06-22T21:49:00.000ZChart Master: Is it time to buy biotech?https://www.pharmaradar360.com/article/serratiopeptidase-pharmaceutical-enzyme-market-growth-forecast-to-2035-bioproces-2e7031a9f6270265Pharma Surgeen2026-06-22T21:26:25.000ZSerratiopeptidase Pharmaceutical Enzyme Market Growth Forecast to 2035: Bioprocessing and Therapeutic Demand Accelerate - News and Statisticshttps://www.pharmaradar360.com/article/biotech-rivalry-between-us-china-intensifies-poll-752b3c9a69236682Pharma Surgeen2026-06-22T21:15:12.000ZBiotech rivalry between US, China intensifies: Pollhttps://www.pharmaradar360.com/article/biotech-firms-add-financial-leaders-in-2026-918d3e7fe4e6bf35Pharma Surgeen2026-06-22T21:06:56.000ZBiotech firms add financial leaders in 2026https://www.pharmaradar360.com/article/new-paper-beyond-the-biotech-race-right-sizing-u-s-china-competition-in-a-human-fc548a178583314cPharma Surgeen2026-06-22T21:03:27.000ZNew Paper | Beyond the Biotech Race — Right-Sizing U.S.-China Competition in a Human-Centered Industryhttps://www.pharmaradar360.com/article/reuters-health-news-summary-e5ed56d421d9dd52Pharma Surgeen2026-06-22T21:00:43.000ZReuters Health News Summaryhttps://www.pharmaradar360.com/article/pfizer-announces-topline-phase-3-results-for-sigvotatug-vedotin-in-previously-tr-10dd1d3888b63bf3Pharma Surgeen2026-06-22T20:30:00.000ZPfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/fda-launches-effort-to-accelerate-drug-trials-527b522c43a7aad5Pharma Surgeen2026-06-22T19:54:22.000ZFDA Launches Effort to Accelerate Drug Trialshttps://www.pharmaradar360.com/article/legend-biotech-s-car-t-cell-therapy-shows-early-promise-in-sclc-other-tumors-9aae32f8c1d343f9Pharma Surgeen2026-06-22T19:31:59.000ZLegend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumorshttps://www.pharmaradar360.com/article/china-closing-in-but-us-leads-in-biotech-quality-commercial-reach-survey-finds-747b6f7045515d21Pharma Surgeen2026-06-22T19:27:06.000ZChina closing in but US leads in biotech quality, commercial reach, survey findshttps://www.pharmaradar360.com/article/abbvie-acquires-apogee-therapeutics-for-10-9-billion-pharmexec-af5c735154dfd7f4Pharma Surgeen2026-06-22T19:17:43.000ZAbbVie Acquires Apogee Therapeutics for $10.9 Billion | PharmExechttps://www.pharmaradar360.com/article/krystal-biotech-krys-is-up-7-2-after-institutional-ownership-surges-to-sector-le-1bf926d02e57b7c5Pharma Surgeen2026-06-22T18:58:15.000ZKrystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levelshttps://www.pharmaradar360.com/article/insilico-lands-potential-2-5bn-ai-biotech-partnership-fc5a71951a40abb0Pharma Surgeen2026-06-22T18:40:57.000ZInsilico lands potential $2.5bn AI biotech partnershiphttps://www.pharmaradar360.com/article/biotech-spotlight-innovative-laboratory-systems-9f6b22dc93c202d4Pharma Surgeen2026-06-22T18:37:18.000ZBiotech Spotlight: Innovative Laboratory Systemshttps://www.pharmaradar360.com/article/u-s-to-speed-up-early-drug-research-to-better-compete-with-china-63470b3aa9e54e42Pharma Surgeen2026-06-22T18:28:00.000ZU.S. to Speed Up Early Drug Research to Better Compete With Chinahttps://www.pharmaradar360.com/article/innovent-s-trispecific-antibody-ibi3003-advances-into-phase-3-for-relapsed-or-re-1e34914fc5276d31Pharma Surgeen2026-06-22T18:10:02.000ZInnovent's Trispecific Antibody IBI3003 Advances Into Phase 3 for Relapsed or Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/novartis-lays-off-60-workers-at-flatiron-biotech-after-1-4b-acquisition-4b18747c347d10fdPharma Surgeen2026-06-22T18:09:00.000ZNovartis lays off 60 workers at Flatiron biotech after $1.4B acquisitionhttps://www.pharmaradar360.com/article/bulletin-phase-3-clinical-trial-success-for-smart-watch-epilepsy-app-800c1e3b1d55cd98Pharma Surgeen2026-06-22T17:57:01.000ZBulletin: Phase 3 Clinical Trial Success for Smart Watch Epilepsy Apphttps://www.pharmaradar360.com/article/the-new-eu-pharmaceutical-legislation-key-points-for-deal-teams-376fc5d762c5b24ePharma Surgeen2026-06-22T17:56:07.000ZThe New EU Pharmaceutical Legislation: Key Points for Deal Teamshttps://www.pharmaradar360.com/article/recon-abbvie-forges-10-9-billion-deal-with-apogee-us-fda-changes-tack-on-regenxb-c7f48b2c884fc197Pharma Surgeen2026-06-22T17:56:00.000ZRecon: AbbVie forges $10.9 billion deal with Apogee; US FDA changes tack on Regenxbio's rare disease gene therapyhttps://www.pharmaradar360.com/article/fda-s-focus-returns-to-compounding-and-telehealth-another-wave-of-warning-letter-e728d704ba1a2761Pharma Surgeen2026-06-22T17:52:52.000ZFDA’s Focus Returns to Compounding and Telehealth: Another Wave of Warning Lettershttps://www.pharmaradar360.com/article/ustr-launches-section-301-investigation-into-germany-s-underpayment-for-pharmace-9a5b586a67c95829Pharma Surgeen2026-06-22T17:52:37.000ZUSTR Launches Section 301 Investigation into Germany’s Underpayment for Pharmaceutical Productshttps://www.pharmaradar360.com/article/this-biotech-could-become-a-sleeper-hit-305a65076770de50Pharma Surgeen2026-06-22T17:45:00.000ZThis Biotech Could Become a ‘Sleeper’ Hithttps://www.pharmaradar360.com/article/pharma-goes-on-a-spending-spree-snapping-up-biotechs-in-a-hurry-eaf6ed3a0241d3b9Pharma Surgeen2026-06-22T16:55:52.000ZPharma goes on a spending spree, snapping up biotechs in a hurryhttps://www.pharmaradar360.com/article/fda-issues-nationwide-recall-for-popular-cough-drops-here-s-the-full-list-186f3366c7869bdbPharma Surgeen2026-06-22T16:47:59.000ZFDA Issues Nationwide Recall for Popular Cough Drops - Here's the Full Listhttps://www.pharmaradar360.com/article/pharmaceutical-majors-cut-investments-in-germany-eb452cf08c9402cfPharma Surgeen2026-06-22T16:33:51.000ZPharmaceutical Majors Cut Investments in Germanyhttps://www.pharmaradar360.com/article/abbvie-paying-10-9b-to-buy-waltham-biotech-c75ff3193fc59ba5Pharma Surgeen2026-06-22T16:31:26.000ZAbbVie paying $10.9B to buy Waltham biotechhttps://www.pharmaradar360.com/article/sanofi-s-r-d-head-exits-with-ai-biotech-xaira-s-exec-stepping-in-2a086694c6c84724Pharma Surgeen2026-06-22T16:28:25.000ZSanofi’s R&D head exits, with AI biotech Xaira’s exec stepping inhttps://www.pharmaradar360.com/article/to-prevent-the-burn-the-fda-finally-approves-a-new-sunscreen-daae3714c8b1c722Pharma Surgeen2026-06-22T16:20:00.000ZTo Prevent the Burn: The FDA Finally Approves a New Sunscreenhttps://www.pharmaradar360.com/article/oppenheimer-raises-definium-therapeutics-stock-price-target-on-trial-data-866b72e2f0c3737fPharma Surgeen2026-06-22T16:20:00.000ZOppenheimer raises Definium Therapeutics stock price target on trial datahttps://www.pharmaradar360.com/article/test-post-3d12995c1a7d7bf2Pharma Surgeen2026-06-22T16:11:40.000ZTest posthttps://www.pharmaradar360.com/article/abbvie-to-acquire-apogee-therapeutics-for-10-9b-73e470411c525835Pharma Surgeen2026-06-22T15:55:04.000ZAbbVie to Acquire Apogee Therapeutics for $10.9Bhttps://www.pharmaradar360.com/article/fda-recall-is-your-blood-pressure-medication-affected-18e8c9aaf6d08ca4Pharma Surgeen2026-06-22T15:52:40.000ZFDA Recall: Is your blood pressure medication affected?https://www.pharmaradar360.com/article/insilico-announces-collaboration-with-sk-biopharmaceutical-for-ai-powered-cns-tr-93d4bf0b7e8c1453Pharma Surgeen2026-06-22T15:51:33.000ZInsilico Announces Collaboration with SK Biopharmaceutical for AI-Powered CNS Treatmenthttps://www.pharmaradar360.com/article/uniqure-s-experimental-drug-shows-early-promise-in-difficult-to-treat-epilepsy-f1e1c6a86738bddePharma Surgeen2026-06-22T15:51:29.000ZuniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsyhttps://www.pharmaradar360.com/article/fda-to-launch-pilot-program-to-speed-up-early-stage-clinical-trials-e125885c8044f375Pharma Surgeen2026-06-22T15:49:32.000ZFDA to launch pilot program to speed up early-stage clinical trialshttps://www.pharmaradar360.com/article/fda-issues-complete-response-letter-for-cytisinicline-nda-citing-manufacturing-d-1cd42e216802baf2Pharma Surgeen2026-06-22T15:48:12.000ZFDA Issues Complete Response Letter for Cytisinicline NDA, Citing Manufacturing Deficiencieshttps://www.pharmaradar360.com/article/fda-issues-crl-for-cytisinicline-for-smoking-cessation-in-adults-d327221192ddfeecPharma Surgeen2026-06-22T15:48:03.000ZFDA Issues CRL for Cytisinicline for Smoking Cessation in Adultshttps://www.pharmaradar360.com/article/us-fda-declines-to-approve-achieve-life-sciences-smoking-cessation-drug-9975e843938b52dfPharma Surgeen2026-06-22T15:45:55.000ZUS FDA declines to approve Achieve Life Sciences' smoking-cessation drughttps://www.pharmaradar360.com/article/enjoy-the-hot-weather-but-stay-safe-nhsggc-advice-for-mini-heatwave-95b7abe003760c56Pharma Surgeen2026-06-22T15:45:00.000ZEnjoy the hot weather but stay safe: NHSGGC advice for mini-heatwavehttps://www.pharmaradar360.com/article/fda-declines-to-approve-achieve-life-sciences-smoking-cessation-drug-q4-resubmis-28146f7b0c3f71b8Pharma Surgeen2026-06-22T15:44:44.000ZFDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission Plannedhttps://www.pharmaradar360.com/article/beyond-the-biotech-race-right-sizing-u-s-china-competition-in-a-human-centered-i-ae5d228824c3ea84Pharma Surgeen2026-06-22T15:43:21.000ZBeyond the Biotech Race — Right-Sizing U.S.-China Competition in a Human-Centered Industryhttps://www.pharmaradar360.com/article/2026-un-high-level-meeting-on-hiv-aids-2d236c15b6583a34Pharma Surgeen2026-06-22T15:43:16.000Z2026 UN High-Level Meeting on HIV/AIDShttps://www.pharmaradar360.com/article/engineers-test-validate-novel-method-to-improve-pharmaceutical-research-and-deve-54be41fd93792507Pharma Surgeen2026-06-22T15:40:07.000ZEngineers test, validate novel method to improve pharmaceutical research and developmenthttps://www.pharmaradar360.com/article/dhsc-spending-over-500-9d0eec9bf491adbdPharma Surgeen2026-06-22T15:31:28.000ZDHSC spending over £500https://www.pharmaradar360.com/article/dhsc-spending-over-500-may-2026-db6ae840e2e515bePharma Surgeen2026-06-22T15:31:20.000ZDHSC: spending over £500, May 2026https://www.pharmaradar360.com/article/machine-learning-based-drug-renal-clearance-predictor-development-and-applicatio-88cc40c758f9c7ffPharma Surgeen2026-06-22T15:20:42.000ZMachine Learning based drug renal clearance predictor development and applicationhttps://www.pharmaradar360.com/article/chemaxon-retires-jchem-for-office-lite-da9f717867504070Pharma Surgeen2026-06-22T15:17:17.000ZChemaxon retires JChem for Office Litehttps://www.pharmaradar360.com/article/why-do-some-children-get-sicker-from-the-flu-than-other-kids-and-how-do-vaccines-74cb40238c44138aPharma Surgeen2026-06-22T15:17:14.000ZWhy Do Some Children Get Sicker From the Flu Than Other Kids and How Do Vaccines Play a Role?https://www.pharmaradar360.com/article/fda-backs-entera-bio-s-750-patient-osteoporosis-trial-for-eb613-693ffa8a17a67179Pharma Surgeen2026-06-22T15:17:07.000ZFDA backs Entera Bio’s 750-patient osteoporosis trial for EB613https://www.pharmaradar360.com/article/leaf4life-engages-phase-advance-to-predict-clinical-outcomes-for-16-phase-3-tria-6188300926a7527dPharma Surgeen2026-06-22T15:11:10.000ZLeaf4Life Engages Phase Advance To Predict Clinical Outcomes for 16 Phase 3 Trialshttps://www.pharmaradar360.com/article/ukhsa-privacy-notice-0e7ed345cb406e76Pharma Surgeen2026-06-22T15:06:08.000ZUKHSA privacy noticehttps://www.pharmaradar360.com/article/fda-announces-recall-of-common-blood-pressure-medication-d21c3f4d8d1d7881Pharma Surgeen2026-06-22T15:04:55.000ZFDA Announces Recall of Common Blood Pressure Medicationhttps://www.pharmaradar360.com/article/fda-launches-new-pilot-to-speed-early-stage-drug-development-58b1b86f7c00b1dcPharma Surgeen2026-06-22T15:03:00.000ZFDA Launches New Pilot to Speed Early-Stage Drug Developmenthttps://www.pharmaradar360.com/article/lilly-declares-third-quarter-2026-dividend-78b7482ce78a846fPharma Surgeen2026-06-22T15:00:00.000ZLilly declares third-quarter 2026 dividendhttps://www.pharmaradar360.com/article/merck-reports-positive-phase-3-tulisokibart-results-8fb7e700065dd027Pharma Surgeen2026-06-22T14:53:00.000ZMerck reports positive Phase 3 tulisokibart resultshttps://www.pharmaradar360.com/article/oxford-biotherapeutics-third-partnered-programme-with-boehringer-ingelheim-enter-2057b8ea888872d4Pharma Surgeen2026-06-22T14:42:40.000ZOxford BioTherapeutics’ Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3https://www.pharmaradar360.com/article/abbvie-deepens-immunology-legacy-in-10-9bn-apogee-buyout-8cbee8b8a01dbb67Pharma Surgeen2026-06-22T14:41:45.000ZAbbVie deepens immunology legacy in $10.9bn Apogee buyouthttps://www.pharmaradar360.com/article/letter-to-baroness-casey-progress-on-adult-social-care-reform-recommendations-e4ba38a0b5ae62cePharma Surgeen2026-06-22T14:39:55.000ZLetter to Baroness Casey: progress on adult social care reform recommendationshttps://www.pharmaradar360.com/article/achieve-life-sciences-receives-fda-rejection-on-manufacturing-issues-7212668f1188a4c4Pharma Surgeen2026-06-22T14:38:31.000ZAchieve Life Sciences receives FDA rejection on manufacturing issueshttps://www.pharmaradar360.com/article/here-s-why-you-should-add-lxrx-stock-to-your-portfolio-now-3348713da485170ePharma Surgeen2026-06-22T14:36:00.000ZHere's Why You Should Add LXRX Stock to Your Portfolio Nowhttps://www.pharmaradar360.com/article/abbvie-deepens-immunology-legacy-in-10-9bn-apogee-buyout-053ec59402f1cc3dPharma Surgeen2026-06-22T14:33:28.000ZAbbVie deepens immunology legacy in $10.9bn Apogee buyouthttps://www.pharmaradar360.com/article/merck-s-ibd-drug-from-10-8b-prometheus-deal-claims-its-first-phase-3-win-00c81de7f718bba8Pharma Surgeen2026-06-22T14:32:00.000ZMerck’s IBD drug from $10.8B Prometheus deal claims its first Phase 3 winhttps://www.pharmaradar360.com/article/menb-vaccination-eligible-residential-further-education-settings-ea1c926b97083608Pharma Surgeen2026-06-22T14:31:58.000ZMenB vaccination: eligible residential further education settingshttps://www.pharmaradar360.com/article/fda-cites-manufacturing-issues-for-cytisinicline-ab59094988eb2fdcPharma Surgeen2026-06-22T14:25:20.000ZFDA Cites Manufacturing Issues for Cytisiniclinehttps://www.pharmaradar360.com/article/women-s-college-hospital-launches-trauma-therapy-network-of-ontario-16caf432205dd826Pharma Surgeen2026-06-22T14:24:54.000ZWomen’s College Hospital launches Trauma Therapy Network of Ontariohttps://www.pharmaradar360.com/article/lonza-and-indupro-announce-licensing-agreement-to-advance-next-generation-adc-th-a7baed30dd6f2f45Pharma Surgeen2026-06-22T14:20:38.000ZLonza and InduPro Announce Licensing Agreement to Advance Next-Generation ADC Therapeuticshttps://www.pharmaradar360.com/article/us-to-investigate-germany-s-proposed-drug-spending-reforms-deea9e2183f697f7Pharma Surgeen2026-06-22T14:14:27.000ZUS to investigate Germany's proposed drug spending reformshttps://www.pharmaradar360.com/article/vaccine-update-issue-371-may-2026-nin-special-35bf814080bca537Pharma Surgeen2026-06-22T14:10:15.000ZVaccine update: issue 371, May 2026, NIN specialhttps://www.pharmaradar360.com/article/purdue-engineers-test-validate-novel-method-to-improve-pharmaceutical-r-d-95070b87f634b700Pharma Surgeen2026-06-22T14:09:38.000ZPurdue engineers test, validate novel method to improve pharmaceutical R&Dhttps://www.pharmaradar360.com/article/abbvie-to-acquire-apogee-therapeutics-in-10-billion-deal-b192d9eb54fdfafdPharma Surgeen2026-06-22T14:06:02.000ZAbbVie to Acquire Apogee Therapeutics in $10 Billion Dealhttps://www.pharmaradar360.com/article/america-is-losing-ground-to-china-in-clinical-research-and-medical-innovation-c5b5431505a9a74cPharma Surgeen2026-06-22T14:05:16.000ZAmerica is losing ground to China in clinical research and medical innovationhttps://www.pharmaradar360.com/article/offworld-biotech-installing-nemuco-in-biolab-on-the-international-space-station-9c9b1789ebcae427Pharma Surgeen2026-06-22T14:04:42.000ZOffworld Biotech: Installing NEMUCO In BioLab On The International Space Stationhttps://www.pharmaradar360.com/article/viiv-healthcare-advances-paediatric-hiv-regulatory-submissions-with-fda-priority-92ffa61c723ee413Pharma Surgeen2026-06-22T14:03:32.000ZViiV Healthcare advances paediatric HIV regulatory submissions with FDA Priority Review for Tivicay PD and EMA validation of marketing application for Tivicayhttps://www.pharmaradar360.com/article/volontariato-28-06-un-concerto-per-sostenere-l-associazione-amici-della-clinica-9f7a522d273e777cPharma Surgeen2026-06-22T14:00:00.000Z#VOLONTARIATO [28.06] Un concerto per sostenere l'Associazione Amici della Clinica Neurochirurgicahttps://www.pharmaradar360.com/article/brain-infiltrating-t-cells-linked-to-social-deficits-in-autism-mouse-model-0452a67a39058a5fPharma Surgeen2026-06-22T13:54:27.000ZBrain-Infiltrating T Cells Linked to Social Deficits in Autism Mouse Modelhttps://www.pharmaradar360.com/article/breast-milk-fatty-acid-shapes-immune-development-in-mice-63a957f5fcfc488cPharma Surgeen2026-06-22T13:48:46.000ZBreast Milk Fatty Acid Shapes Immune Development in Micehttps://www.pharmaradar360.com/article/abbvie-seals-10-9b-deal-to-acquire-waltham-biotech-apogee-therapeutics-dae2fd37fe196ef8Pharma Surgeen2026-06-22T13:34:00.000ZAbbVie seals $10.9B deal to acquire Waltham biotech Apogee Therapeuticshttps://www.pharmaradar360.com/article/another-big-deal-another-sign-biotech-m-a-is-back-34baba61e0a6aa66Pharma Surgeen2026-06-22T13:22:37.000ZAnother big deal, another sign biotech M&A is backhttps://www.pharmaradar360.com/article/pride-month-clinical-research-as-activism-92d0a7b7716cb2dbPharma Surgeen2026-06-22T13:22:07.000ZPride Month: Clinical Research as Activismhttps://www.pharmaradar360.com/article/creative-medical-gets-fda-clearance-to-add-15-patients-in-olastrocel-trial-b330b35d801eff2dPharma Surgeen2026-06-22T13:15:00.000ZCreative Medical gets FDA clearance to add 15 patients in Olastrocel trialhttps://www.pharmaradar360.com/article/wissenschaftsjahr-2026-vier-forderprojekte-zur-wissenschaftskommunikation-in-hei-203cc78b0448f0acPharma Surgeen2026-06-22T13:13:41.000ZWissenschaftsjahr 2026: Vier Förderprojekte zur Wissenschaftskommunikation in Heidelberg und Mannheimhttps://www.pharmaradar360.com/article/genetische-diagnostik-leicht-erklart-mit-generation-genom-dein-code-deine-zukunf-9cd6add8b5a67f4aPharma Surgeen2026-06-22T13:13:12.000ZGenetische Diagnostik leicht erklärt mit „Generation Genom – Dein Code. Deine Zukunft.“https://www.pharmaradar360.com/article/von-a-wie-adhs-bis-z-wie-zukunftsangst-social-media-projekt-klart-zu-psychischer-635933a36252d2a7Pharma Surgeen2026-06-22T13:12:45.000ZVon A wie ADHS bis Z wie Zukunftsangst: Social-Media-Projekt klärt zu psychischer Gesundheit aufhttps://www.pharmaradar360.com/article/mit-rollenspielen-digitale-medizin-erleben-77d482feb31a8744Pharma Surgeen2026-06-22T13:12:19.000ZMit Rollenspielen digitale Medizin erlebenhttps://www.pharmaradar360.com/article/marius-pharmaceuticals-applauds-fda-s-proposed-testosterone-labeling-updates-as-23c49efe850ed947Pharma Surgeen2026-06-22T13:11:16.000ZMarius Pharmaceuticals Applauds FDA’s Proposed Testosterone Labeling Updates as a Turning Point for Men’s Healthhttps://www.pharmaradar360.com/article/healthscience4all-gemeinsam-gesundheit-machen-dced272207476e45Pharma Surgeen2026-06-22T13:11:00.000Z„HealthScience4All“: Gemeinsam Gesundheit machenhttps://www.pharmaradar360.com/article/8-of-the-most-expensive-drugs-in-biopharma-unraveling-the-costliest-medications-0987739455714809Pharma Surgeen2026-06-22T13:00:00.000Z8 of the most expensive drugs in biopharma: Unraveling the costliest medicationshttps://www.pharmaradar360.com/article/education-alumnae-lead-cheers-in-canes-crew-2caf84bb2bf5e5cdPharma Surgeen2026-06-22T12:58:24.000ZEducation alumnae lead cheers in Canes Crewhttps://www.pharmaradar360.com/article/nuvectis-expands-pipeline-with-haisco-licensing-agreement-for-two-clinical-stage-1928ff791f91b125Pharma Surgeen2026-06-22T12:53:18.000ZNuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)https://www.pharmaradar360.com/article/poll-what-s-causing-the-spike-in-weight-loss-drug-mistakes-c1c377c03835652bPharma Surgeen2026-06-22T12:51:22.000ZPoll: What's causing the spike in weight-loss drug mistakes?https://www.pharmaradar360.com/article/dhsc-one-off-statistical-releases-a8a8056e5d3d3dabPharma Surgeen2026-06-22T12:34:11.000ZDHSC one-off statistical releaseshttps://www.pharmaradar360.com/article/estimated-impact-of-the-introduction-of-the-single-patient-record-b914a47d046c4557Pharma Surgeen2026-06-22T12:33:00.000ZEstimated impact of the introduction of the single patient recordhttps://www.pharmaradar360.com/article/nhs-england-recruiting-for-cdio-of-online-hospital-trust-5822c969335f44efPharma Surgeen2026-06-22T12:30:44.000ZNHS England recruiting for CDIO of online hospital trusthttps://www.pharmaradar360.com/article/achieve-life-fda-rejects-cytisinicline-filing-over-manufacturing-issues-d146bc5162910096Pharma Surgeen2026-06-22T12:30:00.000ZAchieve Life FDA rejects cytisinicline filing over manufacturing issueshttps://www.pharmaradar360.com/article/achieve-life-sciences-receives-complete-response-letter-from-fda-for-cytisinicli-3a51583b82abaff9Pharma Surgeen2026-06-22T12:30:00.000ZAchieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDAhttps://www.pharmaradar360.com/article/a-common-vitamin-could-help-fight-one-of-the-deadliest-brain-cancers-d23e540015c0efe6Pharma Surgeen2026-06-22T12:23:53.000ZA common vitamin could help fight one of the deadliest brain cancershttps://www.pharmaradar360.com/article/cough-cold-4e1edfaeb8bb579ePharma Surgeen2026-06-22T12:19:57.000ZCough & coldhttps://www.pharmaradar360.com/article/pain-management-dafd5b7f540add05Pharma Surgeen2026-06-22T12:19:57.000ZPain managementhttps://www.pharmaradar360.com/article/neurology-63b31e258c2d37e4Pharma Surgeen2026-06-22T12:19:57.000ZNeurologyhttps://www.pharmaradar360.com/article/cardiometabolic-aa6d4587a7321130Pharma Surgeen2026-06-22T12:19:57.000ZCardiometabolichttps://www.pharmaradar360.com/article/intim-health-5abe91496210d596Pharma Surgeen2026-06-22T12:19:57.000ZIntim healthhttps://www.pharmaradar360.com/article/gastroenterology-2257d60486d8dee0Pharma Surgeen2026-06-22T12:19:57.000ZGastroenterologyhttps://www.pharmaradar360.com/article/skin-care-ac1ea4a775c70d07Pharma Surgeen2026-06-22T12:19:57.000ZSkin carehttps://www.pharmaradar360.com/article/antibiotics-and-antiseptics-fad87fe3a4f2fedcPharma Surgeen2026-06-22T12:19:57.000ZAntibiotics and antisepticshttps://www.pharmaradar360.com/article/drugs-for-allergy-2fbb7bd128b0ddabPharma Surgeen2026-06-22T12:19:57.000ZDrugs for Allergyhttps://www.pharmaradar360.com/article/fb09a81eb57f8349Pharma Surgeen2026-06-22T12:19:57.000ZПрепарати від застуди та температуриhttps://www.pharmaradar360.com/article/63a817099fb88e7dPharma Surgeen2026-06-22T12:19:57.000ZПрепарати від болю та запаленняhttps://www.pharmaradar360.com/article/c99b583417679c1fPharma Surgeen2026-06-22T12:19:57.000ZНеврологічні препаратиhttps://www.pharmaradar360.com/article/215a3c23a9f76c2bPharma Surgeen2026-06-22T12:19:57.000ZКардіометаболічні препаратиhttps://www.pharmaradar360.com/article/180fc30068f63441Pharma Surgeen2026-06-22T12:19:57.000ZПрепарати для інтимного здоров'яhttps://www.pharmaradar360.com/article/bc702cacb4e44471Pharma Surgeen2026-06-22T12:19:57.000ZПрепарати для застосування у хірургіїhttps://www.pharmaradar360.com/article/6e6d58256e2049adPharma Surgeen2026-06-22T12:19:57.000ZГастроентерологічні препаратиhttps://www.pharmaradar360.com/article/8675dc58a4d32d6cPharma Surgeen2026-06-22T12:19:57.000ZДерматологічні препаратиhttps://www.pharmaradar360.com/article/ee3027f2271a1fa8Pharma Surgeen2026-06-22T12:19:57.000ZАнтибактеріальні препарати та антисептикиhttps://www.pharmaradar360.com/article/d94f61326c64b043Pharma Surgeen2026-06-22T12:19:57.000ZПрепарати при алергіїhttps://www.pharmaradar360.com/article/b3f3f978e8181105Pharma Surgeen2026-06-22T12:19:57.000ZПрепаратиhttps://www.pharmaradar360.com/article/biotech-deals-and-data-lit-a-fire-under-small-caps-46f1dade070cd2d9Pharma Surgeen2026-06-22T12:14:59.000ZBiotech Deals And Data Lit A Fire Under Small Capshttps://www.pharmaradar360.com/article/usz-erhalt-fordergelder-zur-erforschung-von-herzmuskelerkrankungen-9afa8ef28c2ec9daPharma Surgeen2026-06-22T12:14:46.000ZUSZ erhält Fördergelder zur Erforschung von Herzmuskelerkrankungenhttps://www.pharmaradar360.com/article/verrica-starts-phase-3-common-warts-trial-with-first-u-s-patient-26c4964861bb645aPharma Surgeen2026-06-22T12:05:00.000ZVerrica starts Phase 3 common-warts trial with first U.S. patienthttps://www.pharmaradar360.com/article/verrica-pharmaceuticals-announces-first-u-s-patient-dosed-5410e6a88c62adffPharma Surgeen2026-06-22T12:05:00.000ZVerrica Pharmaceuticals Announces First U.S. Patient Dosedhttps://www.pharmaradar360.com/article/insilico-s-ai-design-engine-bags-deal-with-korean-biotech-worth-possible-2-5b-c863d323fa4e5d1cPharma Surgeen2026-06-22T12:04:51.000ZInsilico’s AI design engine bags deal with Korean biotech worth possible $2.5B+https://www.pharmaradar360.com/article/designing-a-comprehensive-pipeline-for-crispr-safety-evaluation-6d2d6db9917b32bePharma Surgeen2026-06-22T12:00:00.000ZDesigning a Comprehensive Pipeline for CRISPR Safety Evaluationhttps://www.pharmaradar360.com/article/abbvie-inks-10-9b-apogee-buyout-to-bag-eczema-prospect-172f6e257c3c7b29Pharma Surgeen2026-06-22T11:59:35.000ZAbbVie inks $10.9B Apogee buyout to bag eczema prospecthttps://www.pharmaradar360.com/article/andrew-mcewan-consultant-2b597fc76d49a217Pharma Surgeen2026-06-22T11:55:26.000ZAndrew McEwan - Consultanthttps://www.pharmaradar360.com/article/german-cancer-award-for-scientists-at-the-medical-faculty-heidelberg-a93243caaa070438Pharma Surgeen2026-06-22T11:49:38.000ZGerman Cancer Award for Scientists at the Medical Faculty Heidelberghttps://www.pharmaradar360.com/article/using-ai-to-close-the-post-market-design-loop-greenlight-guru-cb53504b2f3062c9Pharma Surgeen2026-06-22T11:40:35.000ZUsing AI to close the post-market design loop | Greenlight Guruhttps://www.pharmaradar360.com/article/from-fragmented-reporting-to-real-time-foresight-what-the-fda-s-aems-means-for-p-16c11c54d07fea9cPharma Surgeen2026-06-22T11:35:24.000ZFrom fragmented reporting to real-time foresight: What the FDA’s AEMS means for pharmacovigilancehttps://www.pharmaradar360.com/article/les-hopitaux-universitaires-de-strasbourg-remportent-le-challenge-des-foulees-ec-bf6b779392b0daabPharma Surgeen2026-06-22T11:35:15.000ZLes Hôpitaux Universitaires de Strasbourg remportent le Challenge des Foulées éco-solidaires pour la deuxième année consécutivehttps://www.pharmaradar360.com/article/les-hus-informent-et-accompagnent-les-patients-atteints-d-un-cancer-du-rein-a901820ea576070dPharma Surgeen2026-06-22T11:32:58.000ZLes HUS informent et accompagnent les patients atteints d’un cancer du reinhttps://www.pharmaradar360.com/article/insmed-extensive-phase-3-tpip-program-and-revenue-growth-in-q1-2026-strong-buy-7bcbafd5e98bac24Pharma Surgeen2026-06-22T11:30:38.000ZInsmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong Buyhttps://www.pharmaradar360.com/article/covid-19-vaccination-spring-2026-campaign-resources-6896042b62ccb70dPharma Surgeen2026-06-22T11:25:40.000ZCOVID-19 vaccination: spring 2026 campaign resourceshttps://www.pharmaradar360.com/article/uk-public-health-rapid-support-team-uk-phrst-e9ece4baa927d83dPharma Surgeen2026-06-22T11:21:22.000ZUK Public Health Rapid Support Team (UK-PHRST)https://www.pharmaradar360.com/article/carsgen-makes-history-as-china-approves-world-s-first-car-t-therapy-for-solid-tu-b6484931247389ebPharma Surgeen2026-06-22T11:21:00.000ZCARsgen makes history as China approves world's first CAR-T therapy for solid tumorshttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccination-for-older-adults-b709407e14b34df9Pharma Surgeen2026-06-22T11:19:44.000ZRespiratory syncytial virus (RSV): vaccination for older adultshttps://www.pharmaradar360.com/article/exclusive-nsf-slashes-research-programs-to-support-new-tech-initiative-insiders-efd3e7eb7a1eff80Pharma Surgeen2026-06-22T11:15:00.000ZExclusive: NSF slashes research programs to support new tech initiative, insiders sayhttps://www.pharmaradar360.com/article/definium-lsd-therapy-helped-patients-with-major-depression-in-late-stage-trial-45fd7423ddb1ded7Pharma Surgeen2026-06-22T11:04:05.000ZDefinium LSD therapy helped patients with major depression in late-stage trialhttps://www.pharmaradar360.com/article/ukhsa-issues-red-heat-health-alerts-across-england-3ab1f8a5ec9bfc1dPharma Surgeen2026-06-22T11:01:07.000ZUKHSA issues red heat-health alerts across Englandhttps://www.pharmaradar360.com/article/moonlake-mltx-reveals-robust-phase-3-hs-data-and-targets-2026-bla-filing-6cc9bb09ebf5fc7fPharma Surgeen2026-06-22T11:00:32.000ZMoonLake (MLTX) reveals robust Phase 3 HS data and targets 2026 BLA filinghttps://www.pharmaradar360.com/article/definium-s-lsd-formula-produces-best-data-ever-seen-in-a-pivotal-depression-tria-2a84b96d45b601daPharma Surgeen2026-06-22T11:00:00.000ZDefinium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO sayshttps://www.pharmaradar360.com/article/definium-therapeutics-announces-positive-topline-results-from-phase-3-emerge-stu-706b36d30f9bd472Pharma Surgeen2026-06-22T11:00:00.000ZDefinium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorderhttps://www.pharmaradar360.com/article/a-dose-of-disruption-read-the-full-investigative-series-on-empower-711ba25d4b514405Pharma Surgeen2026-06-22T11:00:00.000ZA Dose of Disruption: Read the full investigative series on Empowerhttps://www.pharmaradar360.com/article/helmed-by-sanofi-vet-bionyra-emerges-with-165m-and-three-licensed-i-i-assets-292e6d9c5a3556bfPharma Surgeen2026-06-22T11:00:00.000ZHelmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assetshttps://www.pharmaradar360.com/article/abbvie-to-acquire-apogee-therapeutics-deepening-immunology-portfolio-9b2e7536a11549b2Pharma Surgeen2026-06-22T11:00:00.000ZAbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfoliohttps://www.pharmaradar360.com/article/labcorp-announces-nationwide-availability-of-colosense-the-first-fda-approved-rn-068f3933db6b7cf8Pharma Surgeen2026-06-22T11:00:00.000ZLabcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Testhttps://www.pharmaradar360.com/article/ukhsa-update-on-the-hantavirus-cruise-ship-outbreak-3c646fc27267b263Pharma Surgeen2026-06-22T10:52:28.000ZUKHSA update on the hantavirus cruise ship outbreakhttps://www.pharmaradar360.com/article/hlth-europe-2026-enriching-the-patient-journey-with-health-technologies-9e826b27d27b1e0dPharma Surgeen2026-06-22T10:48:22.000ZHLTH Europe 2026: enriching the patient journey with health technologieshttps://www.pharmaradar360.com/article/renewal-of-vmps-2026-fcd9b4de0763265cPharma Surgeen2026-06-22T10:47:42.000ZRENEWAL OF VMPs 2026https://www.pharmaradar360.com/article/merck-s-tulisokibart-met-primary-and-key-secondary-endpoints-in-the-phase-3-atla-85af5c6c78bad7b8Pharma Surgeen2026-06-22T10:45:00.000ZMerck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)https://www.pharmaradar360.com/article/uk-mhra-sets-path-for-puberty-blocker-trial-to-continue-62b14910416be8b1Pharma Surgeen2026-06-22T10:44:08.000ZUK MHRA sets path for puberty blocker trial to continuehttps://www.pharmaradar360.com/article/moderna-s-mrna-flu-vaccine-passes-fda-adcom-review-underway-5cc6b2e1754d565cPharma Surgeen2026-06-22T10:43:25.000ZModerna’s mRNA flu vaccine passes FDA AdCom, review underwayhttps://www.pharmaradar360.com/article/2026-e15cba17a9db6bebPharma Surgeen2026-06-22T10:42:43.000ZΑΝΑΝΕΩΣΕΙΣ ΚΤΗΝΙΑΤΡΙΚΩΝ ΠΡΟΪΟΝΤΩΝ 2026https://www.pharmaradar360.com/article/kither-biotech-concludes-phase-i-study-of-kit2014-22007ca816480c6dPharma Surgeen2026-06-22T10:34:38.000ZKither Biotech concludes Phase I study of KIT2014https://www.pharmaradar360.com/article/butterfly-that-barely-ages-could-help-unlock-longevity-secrets-595f4da50f791637Pharma Surgeen2026-06-22T10:30:08.000ZButterfly that barely ages could help unlock longevity secretshttps://www.pharmaradar360.com/article/post-marketing-oncology-studies-enabling-faster-recruitment-and-lower-costs-4e5922e109d7a80bPharma Surgeen2026-06-22T10:21:14.000ZPost-marketing oncology studies: Enabling faster recruitment and lower costshttps://www.pharmaradar360.com/article/post-marketing-oncology-studies-enabling-faster-recruitment-and-lower-costs-d21e482d9e74bdd7Pharma Surgeen2026-06-22T10:17:06.000ZPost-marketing oncology studies: Enabling faster recruitment and lower costshttps://www.pharmaradar360.com/article/innovo-therapeutics-scores-korean-phase-3-approval-for-scar-treatment-inv-001-65c52f19b3556c62Pharma Surgeen2026-06-22T10:13:36.000ZInnovo Therapeutics scores Korean phase 3 approval for scar treatment, INV-001https://www.pharmaradar360.com/article/tvtx-lgnd-stocks-in-spotlight-ahead-of-monday-s-fda-call-on-kidney-drug-filspari-fa6238499aaae213Pharma Surgeen2026-06-22T10:10:50.000ZTVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filsparihttps://www.pharmaradar360.com/article/in-another-reversal-for-rare-disease-field-fda-to-reconsider-regenxbio-gene-ther-4f9851448f8a51ccPharma Surgeen2026-06-22T10:09:00.000ZIn another reversal for rare disease field, FDA to reconsider Regenxbio gene therapyhttps://www.pharmaradar360.com/article/the-benefits-and-challenges-of-100-percent-us-based-manufacturing-ce4903f826bc8aeaPharma Surgeen2026-06-22T10:00:00.000ZThe Benefits and Challenges of 100 Percent US-Based Manufacturinghttps://www.pharmaradar360.com/article/us-to-investigate-germany-s-proposed-drug-spending-reforms-e84e15d708054becPharma Surgeen2026-06-22T09:56:00.000ZUS to investigate Germany's proposed drug spending reformshttps://www.pharmaradar360.com/article/icon-selects-microsoft-as-a-preferred-technology-partner-to-power-ai-enabled-cli-6d62bb6d794b913dPharma Surgeen2026-06-22T09:53:36.000ZICON Selects Microsoft as a Preferred Technology Partner to Power AI-Enabled Clinical Developmenthttps://www.pharmaradar360.com/article/heidelberg-among-the-top-three-universities-in-germany-c0776f33e63073ecPharma Surgeen2026-06-22T09:52:53.000ZHeidelberg Among the “Top Three” Universities in Germanyhttps://www.pharmaradar360.com/article/congressional-budget-office-contends-provider-wins-undermining-no-surprises-act-4f643b550a354651Pharma Surgeen2026-06-22T09:51:35.000ZCongressional Budget Office contends provider wins undermining No Surprises Acthttps://www.pharmaradar360.com/article/regulatory-round-up-22-june-2026-c0277841a453a61cPharma Surgeen2026-06-22T09:51:12.000ZRegulatory round-up: 22 June 2026https://www.pharmaradar360.com/article/alnylam-scolded-over-promotional-activity-after-pfizer-complaint-fcdd12aefceea3f0Pharma Surgeen2026-06-22T09:46:00.000ZAlnylam scolded over promotional activity after Pfizer complainthttps://www.pharmaradar360.com/article/merck-s-anti-tl1a-antibody-from-prometheus-buyout-passes-ph-3-test-in-ulcerative-f28afb7f0bf25239Pharma Surgeen2026-06-22T09:36:00.000ZMerck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitishttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-21-june-2026-6a0eead6dccb0816Pharma Surgeen2026-06-22T09:35:35.000ZWeekly all-cause mortality surveillance: week ending 21 June 2026https://www.pharmaradar360.com/article/world-refugee-day-showing-solidarity-with-refugees-in-south-africa-1c171c82a338e056Pharma Surgeen2026-06-22T09:14:19.000ZWorld Refugee Day: Showing solidarity with refugees in South Africahttps://www.pharmaradar360.com/article/what-the-first-joint-clinical-assessment-jca-report-tells-us-about-the-next-era-798d89dcf0acdf20Pharma Surgeen2026-06-22T09:11:56.000ZWhat the first Joint Clinical Assessment (JCA) report tells us about the next era of integrated evidence planning and access strategyhttps://www.pharmaradar360.com/article/la-adquisicion-de-rois-phoenix-marca-un-nuevo-hito-en-la-internacionalizacion-de-2fa01139f7d26eabPharma Surgeen2026-06-22T09:11:14.000ZLa adquisición de ROIS PHOENIX marca un nuevo hito en la internacionalización del negocio de fabricación a terceros de ROIShttps://www.pharmaradar360.com/article/the-evolution-of-the-adc-market-and-what-it-means-for-commercial-packaging-714a26e7f1767217Pharma Surgeen2026-06-22T09:03:42.000ZThe evolution of the ADC market – and what it means for commercial packaginghttps://www.pharmaradar360.com/article/sun-pharma-to-acquire-innovcare-lifesciences-for-28-7m-f87cae1880af8055Pharma Surgeen2026-06-22T09:03:35.000ZSun Pharma to acquire Innovcare Lifesciences for $28.7mhttps://www.pharmaradar360.com/article/women-living-with-ms-take-to-the-stage-in-powerful-showcase-7f459939722c5587Pharma Surgeen2026-06-22T09:03:17.000ZWomen living with MS take to the stage in powerful showcasehttps://www.pharmaradar360.com/article/does-drinking-juice-soda-during-childhood-increase-the-risk-of-high-blood-pressu-7ecd15e132fabe8ePharma Surgeen2026-06-22T09:00:00.000ZDoes drinking juice, soda during childhood increase the risk of high blood pressure?https://www.pharmaradar360.com/article/first-participant-receives-evategrel-in-curegene-s-trial-e95a1d08784001acPharma Surgeen2026-06-22T08:55:41.000ZFirst participant receives Evategrel in CureGene’s trialhttps://www.pharmaradar360.com/article/algae-microbots-take-aim-at-bladder-cancer-7c544810e644309fPharma Surgeen2026-06-22T08:51:26.000ZAlgae microbots take aim at bladder cancerhttps://www.pharmaradar360.com/article/ildong-pharmaceutical-group-to-attend-bio-usa-advance-global-partnering-for-glp-fdb4ba669c063225Pharma Surgeen2026-06-22T08:43:42.000ZIldong Pharmaceutical Group to attend BIO USA, advance global partnering for GLP-1 obesity drug candidateshttps://www.pharmaradar360.com/article/post-covid-syndrom-blutwasche-zeigt-in-studie-keinen-nutzen-fur-betroffene-8aec8256c4d917c0Pharma Surgeen2026-06-22T08:31:45.000ZPost-Covid-Syndrom: Blutwäsche zeigt in Studie keinen Nutzen für Betroffenehttps://www.pharmaradar360.com/article/research-as-a-constant-balancing-act-between-opportunities-and-risks-f86e89733ba4237bPharma Surgeen2026-06-22T08:20:09.000ZResearch as a Constant Balancing Act between Opportunities and Riskshttps://www.pharmaradar360.com/article/muttermilch-fur-fruhgeborene-7f4dfe8063e439dePharma Surgeen2026-06-22T08:13:10.000ZMuttermilch für Frühgeborenehttps://www.pharmaradar360.com/article/acuerdos-aprobados-y-votaciones-6a9c9d85a3a28004Pharma Surgeen2026-06-22T08:11:47.000ZAcuerdos aprobados y votacioneshttps://www.pharmaradar360.com/article/sanofi-pangaea-ink-ai-partnership-deal-to-detect-underdiagnosed-genetic-disease-ad2711fed31fbd68Pharma Surgeen2026-06-22T08:08:00.000ZSanofi, Pangaea ink AI partnership deal to detect underdiagnosed genetic diseasehttps://www.pharmaradar360.com/article/japan-approves-sanofi-s-sarclisa-combo-for-mm-treatment-725956350ad515e9Pharma Surgeen2026-06-22T08:01:58.000ZJapan approves Sanofi’s Sarclisa combo for MM treatmenthttps://www.pharmaradar360.com/article/ai-tool-reveals-hidden-organ-damage-caused-by-high-blood-pressure-d26a1ebe0f5d8484Pharma Surgeen2026-06-22T08:00:42.000ZAI tool reveals hidden organ damage caused by high blood pressurehttps://www.pharmaradar360.com/article/hydration-break-advertising-signals-a-lasting-shift-in-global-football-2c4fe8a51b6eea74Pharma Surgeen2026-06-22T08:00:00.000ZHydration break advertising signals a lasting shift in global footballhttps://www.pharmaradar360.com/article/abbvie-inks-10-9b-apogee-buyout-to-bag-hotly-tipped-eczema-prospect-4f42756b71397287Pharma Surgeen2026-06-22T07:59:00.000ZAbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospecthttps://www.pharmaradar360.com/article/prosper-ai-lands-30m-backed-by-andreessen-horowitz-to-build-ai-workforce-for-hea-8842a3d4366871b6Pharma Surgeen2026-06-22T07:46:00.000ZProsper AI lands $30M backed by Andreessen Horowitz to build AI workforce for healthcare operationshttps://www.pharmaradar360.com/article/2026-3-4-7-24-20dc904f5aeba21bPharma Surgeen2026-06-22T07:41:22.000Z2026年度 第3回・第4回 臨床研究教育セミナー開催のお知らせ（7/24開催）https://www.pharmaradar360.com/article/information-about-the-criminal-offence-committed-by-a-former-employee-of-the-uni-ee060b2d6ee29a14Pharma Surgeen2026-06-22T07:08:00.000ZInformation about the criminal offence committed by a former employee of the University of Freiburghttps://www.pharmaradar360.com/article/holland-chair-spurs-innovation-in-public-health-1e60892ce4c00a6ePharma Surgeen2026-06-22T07:00:00.000ZHolland chair spurs innovation in public healthhttps://www.pharmaradar360.com/article/between-heat-exhaustion-and-heat-stroke-what-you-need-to-know-b5fac13ff19ea0b9Pharma Surgeen2026-06-22T07:00:00.000ZBetween Heat Exhaustion and Heat Stroke: What You Need to Knowhttps://www.pharmaradar360.com/article/in-defense-of-the-boxed-warning-f7fda340eaf99cb2Pharma Surgeen2026-06-22T07:00:00.000ZIn Defense of the Boxed Warninghttps://www.pharmaradar360.com/article/unmc-team-publishes-review-article-on-hantavirus-6569e837d3eb2a4dPharma Surgeen2026-06-22T06:58:00.000ZUNMC team publishes review article on Hantavirushttps://www.pharmaradar360.com/article/new-faculty-spotlight-logan-kludt-lawrence-dds-a684a1a813941e79Pharma Surgeen2026-06-22T06:56:00.000ZNew faculty spotlight: Logan Kludt Lawrence, DDShttps://www.pharmaradar360.com/article/moonlake-s-sonelokimab-achieves-67-hiscr75-response-in-phase-3-hs-trial-f7f0cf6da9a6bbd7Pharma Surgeen2026-06-22T06:49:03.000ZMoonLake’s Sonelokimab Achieves 67% HiSCR75 Response in Phase 3 HS Trialhttps://www.pharmaradar360.com/article/fda-approves-moderna-s-new-mrna-based-flu-vaccine-65dde0f3c84e0715Pharma Surgeen2026-06-22T06:40:07.000ZFDA approves Moderna's new mRNA-based flu vaccinehttps://www.pharmaradar360.com/article/ebola-and-hantavirus-can-start-like-the-flu-but-turn-deadly-fast-c41bcd1a3639caaePharma Surgeen2026-06-22T06:30:53.000ZEbola and hantavirus can start like the flu but turn deadly fasthttps://www.pharmaradar360.com/article/powys-teaching-health-board-goes-live-with-better-epma-96a8e50e9fe3277aPharma Surgeen2026-06-22T06:30:39.000ZPowys Teaching Health Board goes live with Better ePMAhttps://www.pharmaradar360.com/article/skydda-dig-infor-resan-se-over-ditt-vaccinationsskydd-e596a86c455487dcPharma Surgeen2026-06-22T06:16:52.000ZSkydda dig inför resan – se över ditt vaccinationsskyddhttps://www.pharmaradar360.com/article/year-to-date-business-update-ahead-of-annual-general-meeting-40631478ea36b1eaPharma Surgeen2026-06-22T06:02:08.000ZYear-to-date business update ahead of Annual General Meetinghttps://www.pharmaradar360.com/article/comment-la-production-hepatique-d-epo-s-eteint-a-la-naissance-24dfced76484851fPharma Surgeen2026-06-22T06:00:00.000ZComment la production hépatique d’EPO s’éteint à la naissancehttps://www.pharmaradar360.com/article/dermatite-eczema-e-scottatura-l-abc-delle-irritazioni-della-pelle-4f84152ee8e319fdPharma Surgeen2026-06-22T05:58:00.000ZDermatite, eczema e scottatura: l'ABC delle irritazioni della pellehttps://www.pharmaradar360.com/article/2027-tour-de-cure-mid-atlantic-cbdfd4a4a883db5cPharma Surgeen2026-06-22T05:14:19.000Z2027 Tour de Cure®: Mid-Atlantichttps://www.pharmaradar360.com/article/2027-tour-de-cure-florida-0fa5e13cec6c739dPharma Surgeen2026-06-22T05:14:19.000Z2027 Tour de Cure®: Floridahttps://www.pharmaradar360.com/article/2027-tour-de-cure-arizona-0efea63f938482ccPharma Surgeen2026-06-22T05:14:19.000Z2027 Tour de Cure®: Arizonahttps://www.pharmaradar360.com/article/2027-step-out-walk-tennessee-1800ca0610479d64Pharma Surgeen2026-06-22T05:14:19.000Z2027 Step Out® Walk: Tennesseehttps://www.pharmaradar360.com/article/2027-step-out-walk-tampa-d991751ab8ce02aePharma Surgeen2026-06-22T05:14:19.000Z2027 Step Out® Walk: Tampahttps://www.pharmaradar360.com/article/2027-step-out-walk-north-texas-62b162c70317fadaPharma Surgeen2026-06-22T05:14:19.000Z2027 Step Out® Walk: North Texashttps://www.pharmaradar360.com/article/2027-step-out-walk-hawaii-12b2b04c8c4c8298Pharma Surgeen2026-06-22T05:14:19.000Z2027 Step Out® Walk: Hawaiihttps://www.pharmaradar360.com/article/2027-step-out-walk-charlotte-9a1e7a1e11085daePharma Surgeen2026-06-22T05:14:19.000Z2027 Step Out® Walk: Charlottehttps://www.pharmaradar360.com/article/innovent-doses-first-patient-in-multiple-myeloma-trial-b21576475e07a93cPharma Surgeen2026-06-22T05:06:58.000ZInnovent doses first patient in multiple myeloma trialhttps://www.pharmaradar360.com/article/bio-2026-cell-and-gene-therapy-sector-must-break-the-mold-to-thrive-4fe03b4af8563984Pharma Surgeen2026-06-22T04:53:00.000ZBIO 2026: Cell and gene therapy sector must break the mold to thrivehttps://www.pharmaradar360.com/article/recce-pharmaceuticals-advances-diabetic-foot-infection-trial-to-pivotal-phase-3-1669068da74fe151Pharma Surgeen2026-06-22T04:02:34.000ZRecce Pharmaceuticals Advances Diabetic Foot Infection Trial to Pivotal Phase 3https://www.pharmaradar360.com/article/fda-cites-four-importers-for-verification-failures-involving-produce-dairy-ingre-1e41ce236c615498Pharma Surgeen2026-06-22T04:02:05.000ZFDA cites four importers for verification failures involving produce, dairy ingredientshttps://www.pharmaradar360.com/article/pharmacogenomics-genetics-drugs-clinical-interplay-f4fe2a84557dbca3Pharma Surgeen2026-06-22T04:01:30.000ZPharmacogenomics Genetics Drugs Clinical Interplayhttps://www.pharmaradar360.com/article/infant-resuscitation-system-correction-ge-healthcare-issues-correction-for-giraf-f6ae418a58c2d32bPharma Surgeen2026-06-22T04:00:00.000ZInfant Resuscitation System Correction: GE HealthCare Issues Correction for Giraffe and Panda Infant Resuscitation Systems and Warmers with a M1091607-R Blenderhttps://www.pharmaradar360.com/article/heart-pump-controller-correction-abiomed-updates-use-instructions-for-automated-9d680a62c9f545eaPharma Surgeen2026-06-22T04:00:00.000ZHeart Pump Controller Correction: Abiomed Updates Use Instructions for Automated Impella Controllershttps://www.pharmaradar360.com/article/sanofi-s-r-d-chief-ashrafian-to-hit-the-exit-as-new-ceo-seeks-to-fix-stuttering-306305e1e65121d6Pharma Surgeen2026-06-22T03:48:00.000ZSanofi's R&D chief Ashrafian to hit the exit as new CEO seeks to fix stuttering pipeline with Roche alumhttps://www.pharmaradar360.com/article/shinsa-cdx-approved-for-identifying-eligible-patients-updated-june-16-2026-54d2f1b7bc99c8c4Pharma Surgeen2026-06-22T03:00:00.000Z[SHINSA]CDx approved for identifying eligible patients (Updated June 16, 2026)https://www.pharmaradar360.com/article/shinsa-list-of-approved-drugs-april-2004-to-february-2026-36a9fdbe61938f13Pharma Surgeen2026-06-22T03:00:00.000Z[SHINSA]List of Approved Drugs: April 2004 to February 2026https://www.pharmaradar360.com/article/moonlake-immunotherapeutics-mltx-reports-positive-phase-3-clin-a8f1d526204dbf56Pharma Surgeen2026-06-22T02:42:23.000ZMoonLake Immunotherapeutics (MLTX) Reports Positive Phase 3 Clinhttps://www.pharmaradar360.com/article/fda-announces-recall-of-great-value-hawaiian-rolls-over-packaging-contamination-5ddade30f26b52a8Pharma Surgeen2026-06-22T01:49:18.000ZFDA Announces Recall of Great Value Hawaiian Rolls Over Packaging Contaminationhttps://www.pharmaradar360.com/article/one-common-fat-may-fuel-type-2-diabetes-while-another-helps-fight-it-d21b2205ad875829Pharma Surgeen2026-06-22T00:25:04.000ZOne common fat may fuel type 2 diabetes while another helps fight ithttps://www.pharmaradar360.com/article/prg-s-tech-receives-therapeutic-use-approval-for-nf2-treatment-trineumin-995f4ec2309eb1abPharma Surgeen2026-06-22T00:15:10.000ZPRG S&Tech Receives Therapeutic Use Approval for NF2 Treatment 'Trineumin'https://www.pharmaradar360.com/article/abbvie-filed-form-8-k-1d7a98a5d89bf343Pharma Surgeen2026-06-22T00:00:00.000ZAbbVie filed Form 8-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-4bf5084d40c43e88Pharma Surgeen2026-06-22T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-06e50b94bb23e808Pharma Surgeen2026-06-22T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/from-1-to-180-how-nice-guidance-helped-us-make-smarter-slide-sheet-choices-eafe070e09e65a94Pharma Surgeen2026-06-22T00:00:00.000ZFrom £1 to £180: how NICE guidance helped us make smarter slide sheet choiceshttps://www.pharmaradar360.com/article/deep-learning-enabled-single-cell-morpholomic-atlas-of-nasal-swabs-distinguishes-faa6339b9aab6bbbPharma Surgeen2026-06-22T00:00:00.000ZDeep learning–enabled single-cell morpholomic atlas of nasal swabs distinguishes chronic inflammation from sinonasal malignancyhttps://www.pharmaradar360.com/article/nucleic-sexual-hormone-receptor-signaling-pathways-in-breast-cancer-function-reg-5a0d531f78e8b3d7Pharma Surgeen2026-06-22T00:00:00.000ZNucleic sexual hormone receptor signaling pathways in breast cancer: function regulation, crosstalk, and therapeutic implicationshttps://www.pharmaradar360.com/article/long-term-health-risks-of-e-cigarettes-after-smoking-cessation-0b5010b57e88e76cPharma Surgeen2026-06-22T00:00:00.000ZLong-term health risks of e-cigarettes after smoking cessationhttps://www.pharmaradar360.com/article/a-case-of-artificial-intelligence-enhanced-diagnostics-leading-to-heart-transpla-b78475cff8c90f71Pharma Surgeen2026-06-22T00:00:00.000ZA case of artificial intelligence-enhanced diagnostics leading to heart transplantationhttps://www.pharmaradar360.com/article/biological-aging-and-generational-shifts-in-early-onset-cancer-risk-319a99ff0f8777baPharma Surgeen2026-06-22T00:00:00.000ZBiological aging and generational shifts in early-onset cancer riskhttps://www.pharmaradar360.com/article/affordable-centimeter-scale-3d-microscopy-with-submicrometer-resolution-43ce8c6e9ee3f64fPharma Surgeen2026-06-22T00:00:00.000ZAffordable centimeter-scale 3D microscopy with submicrometer resolutionhttps://www.pharmaradar360.com/article/c-glycoside-synthesis-via-radical-cross-coupling-of-glycohydrazides-584fecfc4c41efb3Pharma Surgeen2026-06-22T00:00:00.000ZC-glycoside synthesis via radical cross-coupling of glycohydrazideshttps://www.pharmaradar360.com/article/stereoretentive-decarbonylative-c-sp-3-c-sp-3-cross-coupling-8b31d8f4b39ea79bPharma Surgeen2026-06-22T00:00:00.000ZStereoretentive decarbonylative C(sp 3 )-C(sp 3 ) cross-couplinghttps://www.pharmaradar360.com/article/isotopic-evidence-for-a-cold-and-distant-origin-of-3i-atlas-edc13ada612fc167Pharma Surgeen2026-06-22T00:00:00.000ZIsotopic evidence for a cold and distant origin of 3I/ATLAShttps://www.pharmaradar360.com/article/make-science-more-reliable-study-people-as-they-go-about-their-lives-cda2ca72bab5b884Pharma Surgeen2026-06-22T00:00:00.000ZMake science more reliable: study people as they go about their liveshttps://www.pharmaradar360.com/article/why-heritage-sites-are-at-risk-in-a-warming-world-and-how-to-save-them-66d16ddfe34c4e2aPharma Surgeen2026-06-22T00:00:00.000ZWhy heritage sites are at risk in a warming world — and how to save themhttps://www.pharmaradar360.com/article/will-ai-spark-a-scientific-renaissance-or-a-diffuse-monoculture-cdbeeef43cef14d0Pharma Surgeen2026-06-22T00:00:00.000ZWill AI spark a scientific renaissance — or a diffuse monoculture?https://www.pharmaradar360.com/article/the-first-ticking-nuclear-clocks-are-here-what-can-they-do-374eea03e8011488Pharma Surgeen2026-06-22T00:00:00.000ZThe first ticking ‘nuclear clocks’ are here — what can they do?https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-88765df961c41d8cPharma Surgeen2026-06-22T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-8d3a38d9a9f2c790Pharma Surgeen2026-06-22T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-2fd7783bb395bef5Pharma Surgeen2026-06-22T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-f6fb7f3135e9649cPharma Surgeen2026-06-22T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fda